CIRM Awards $5.9 Million to Burnham Institute
News Feb 19, 2007
The Burnham Institute for Medical Research (Burnham) will receive $5,925,878 in grants awarded from the California Institute for Regenerative Medicine (CIRM) as part of the first research grants approved under Proposition 71, the Stem Cell Research and Cures Act, adopted by California voters in November 2004.
The Independent Citizen's Oversight Committee, the governing body charged with implementing Proposition 71, has approved the allocation of $45 million to fund 72 grants awarded under CIRM's Scientific Excellence through Exploration and Development (SEED) Grant Program.
"In funding these SEED grants, CIRM is fulfilling its commitment to making a major impact on stem cell science and health care," said Dr. Evan Snyder, Professor and Director of Stem Cell Research at Burnham.
"These are the first grants to support fundamental science. By giving priority to SEED funding, CIRM is supporting early-stage science that could not be funded under current stem cell funding guidelines at the National Institutes of Health," Snyder continued.
At Burnham, the SEED funding will help launch projects each of which will explore a different aspect of stem cell biology in areas of medical relevance ranging from heart disease, Parkinson's, cancer, and neural development, to the development of methods for deriving and culturing human embryonic stem cell lines.
Scientists have used machine learning to train computers to see parts of the cell the human eye cannot easily distinguish. Using 3D images of fluorescently labeled cells, the research team taught computers to find structures inside living cells without fluorescent labels, using only black and white images generated by an inexpensive technique known as brightfield microscopy.READ MORE
The National Institutes of Health announced the launch of a new initiative to help speed the development of cures for sickle cell disease. The Cure Sickle Cell Initiative will take advantage of the latest genetic discoveries and technological advances to move the most promising genetic-based curative therapies safely into clinical trials within five to 10 years.